Coltuximab ravtansine (SAR-3419)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 20:31, 26 November 2014 by Jwarner (talk | contribs)
Jump to navigation Jump to search

Mechanism of action

Antibody-drug conjugate

Preliminary studies

Diffuse large B-cell lymphoma

  1. Abstract: B. Coiffier, V. Ribrag, J. Dupuis, H. Tilly, C. Haioun, F. Morschhauser, T. Lamy, C. Copie-Bergman, O. Brehar, R. Houot, J. M. Lambert, R. Morarui-Zamfir. Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). J Clin Oncol 29: 2011 (suppl; abstr 8017) link to original abstract
Retrieved from "https://hemonc.org/w/index.php?title=Coltuximab_ravtansine_(SAR-3419)&oldid=6141"